Symbols / OTLK $0.35 -10.69%
OTLK Chart
About
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 29.23M |
| Enterprise Value | 57.45M | Income | -102.86M | Sales | 205.70K |
| Book/sh | -0.60 | Cash/sh | 0.10 | Dividend Yield | — |
| Payout | 0.00% | Employees | 17 | IPO | — |
| P/E | — | Forward P/E | -1.24 | PEG | — |
| P/S | 142.11 | P/B | -0.59 | P/C | — |
| EV/EBITDA | -0.98 | EV/Sales | 279.27 | Quick Ratio | 0.18 |
| Current Ratio | 0.35 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.89 | EPS next Y | -0.28 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -209.04% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 11.16% | Profit Margin | 0.00% | Shs Outstand | 83.07M |
| Shs Float | 67.73M | Short Float | 4.45% | Short Ratio | 2.40 |
| Short Interest | — | 52W High | 3.39 | 52W Low | 0.34 |
| Beta | -0.08 | Avg Volume | 5.63M | Volume | 3.39M |
| Target Price | $4.38 | Recom | Buy | Prev Close | $0.39 |
| Price | $0.35 | Change | -10.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.38
Mean price target
2. Current target
$0.35
Latest analyst target
3. DCF / Fair value
$-7.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.35
Low
$0.50
High
$10.00
Mean
$4.38
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Ascendiant Capital | Buy → Buy | $6 |
| 2026-02-18 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2026-02-18 | main | Chardan Capital | Neutral → Neutral | $1 |
| 2026-01-05 | main | Chardan Capital | Neutral → Neutral | $1 |
| 2026-01-02 | main | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-12-22 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2025-09-30 | reit | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2025-09-22 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-08-29 | down | Guggenheim | Buy → Neutral | — |
| 2025-08-29 | down | HC Wainwright & Co. | Buy → Neutral | $1 |
| 2025-08-28 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-08-15 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-06-06 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-02-24 | main | Ascendiant Capital | Buy → Buy | $24 |
| 2025-02-18 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-02-18 | main | Chardan Capital | Neutral → Neutral | $3 |
| 2025-01-17 | reit | Guggenheim | Buy → Buy | $12 |
| 2025-01-17 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-12-02 | down | Chardan Capital | Buy → Neutral | — |
| 2024-11-29 | main | BTIG | Buy → Buy | $9 |
- Outlook Therapeutics takes $18.4M loan at min 9.5% to cut note balance - Stock Titan Mon, 16 Mar 2026 12
- OTLK Stock Crashes 67% in a Week: Here's What You Need to Know - Yahoo Finance Wed, 07 Jan 2026 08
- Gold Supply Outlook: As Prices Rise, Producing Nations Want a Bigger Share - GoldSilver Mon, 16 Mar 2026 15
- New Analyst Forecast: $OTLK Given $0.5 Price Target | OTLK Stock News - Quiver Quantitative Wed, 18 Feb 2026 08
- OTLK Earning Date, Earning Analysis and Earning Prediction - Intellectia AI Sat, 28 Feb 2026 00
- Ascendiant Capital Lowers Price Target for Outlook Therapeutics (OTLK) | OTLK Stock News - GuruFocus Wed, 11 Mar 2026 10
- OTLK Stock Today: January 4 - FDA CRL Extends Approval Timeline - Meyka Sun, 04 Jan 2026 08
- OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug - Zacks Investment Research Fri, 29 Aug 2025 07
- FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices - BioSpace Fri, 02 Jan 2026 08
- Outlook Therapeutics stock plunges after FDA rejects wet AMD drug application - Investing.com Wed, 31 Dec 2025 08
- Private Credit Fears, War Darken Outlook for US Financial Stocks - Yahoo Finance Sat, 14 Mar 2026 13
- First bevacizumab eye drug? Outlook, FDA discuss path for ONS-5010 - Stock Titan hu, 05 Mar 2026 08
- Eye drug firm Outlook Therapeutics expands in Europe, seeks FDA talks - Stock Titan ue, 17 Feb 2026 08
- Biotech offers stock options to lure two new hires at $2.01 a share - Stock Titan Fri, 26 Dec 2025 08
- Outlook Therapeutics (Nasdaq: OTLK) details FDA Type A meeting on ONS-5010 - Stock Titan hu, 05 Mar 2026 22
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4285714 | 6000000 | — | Stock Award(Grant) at price 1.40 per share. | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-27 00:00:00 | I |
| 1 | 3458571 | 7712613 | — | Conversion of Exercise of derivative security at price 2.23 per share. | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-17 00:00:00 | I |
| 2 | 3458571 | 8681013 | — | Conversion of Exercise of derivative security at price 2.51 per share. | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-17 00:00:00 | I |
| 3 | 5000 | 28446 | — | Purchase at price 5.69 per share. | KENYON LAWRENCE A. | Chief Financial Officer | — | 2024-09-26 00:00:00 | D |
| 4 | 714286 | 6157145 | — | Purchase at price 8.62 per share. | SYNTONE VENTURES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-15 00:00:00 | D |
| 5 | 1881 | 22242 | — | Purchase at price 11.82 per share. | HADDADIN YEZAN MUNTHER | Director | — | 2024-03-28 00:00:00 | D |
| 6 | 2305714 | — | — | Stock Award(Grant) at price 0.00 per share. | SUKHTIAN GHIATH M | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-03-18 00:00:00 | I |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 1.03M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.02 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -106.59M | -110.73M | -55.88M | -63.80M |
| TotalUnusualItems | 43.02M | 38.64M | -526.74K | -559.62K |
| TotalUnusualItemsExcludingGoodwill | 43.02M | 38.64M | -526.74K | -559.62K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -62.42M | -75.37M | -58.98M | -66.05M |
| ReconciledDepreciation | 117.05K | 113.86K | 44.19K | 204.69K |
| ReconciledCostOfRevenue | 1.36M | 0.00 | ||
| EBITDA | -63.58M | -72.09M | -56.40M | -64.36M |
| EBIT | -63.69M | -72.21M | -56.45M | -64.56M |
| NetInterestIncome | -193.39K | -2.25M | -1.56M | -1.49M |
| InterestExpense | 283.13K | 3.16M | 2.53M | 1.49M |
| InterestIncome | 89.74K | 906.15K | 971.48K | |
| NormalizedIncome | -104.41M | -114.00M | -58.46M | -65.49M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -62.42M | -75.37M | -58.98M | -66.05M |
| TotalExpenses | 68.48M | 71.70M | 53.13M | 63.07M |
| TotalOperatingIncomeAsReported | -67.06M | -71.70M | -53.13M | -63.07M |
| DilutedAverageShares | 34.80M | 18.55M | 12.51M | 10.60M |
| BasicAverageShares | 34.80M | 18.55M | 12.51M | 10.60M |
| DilutedEPS | -1.79 | -4.06 | -4.72 | -6.20 |
| BasicEPS | -1.79 | -4.06 | -4.72 | -6.20 |
| DilutedNIAvailtoComStockholders | -62.42M | -75.37M | -58.98M | -66.05M |
| NetIncomeCommonStockholders | -62.42M | -75.37M | -58.98M | -66.05M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -62.42M | -75.37M | -58.98M | -66.05M |
| NetIncomeIncludingNoncontrollingInterests | -62.42M | -75.37M | -58.98M | -66.05M |
| NetIncomeContinuousOperations | -62.42M | -75.37M | -58.98M | -66.05M |
| TaxProvision | -1.55M | 2.80K | 2.80K | 2.80K |
| PretaxIncome | -63.98M | -75.36M | -58.98M | -66.05M |
| OtherIncomeExpense | 3.28M | -1.41M | -4.29M | -1.49M |
| OtherNonOperatingIncomeExpenses | -39.60M | -39.95M | -3.76M | -882.90K |
| SpecialIncomeCharges | 0.00 | -577.66K | -1.03M | 0.00 |
| OtherSpecialCharges | 577.66K | 1.03M | ||
| ImpairmentOfCapitalAssets | 0.00 | |||
| EarningsFromEquityInterest | -141.01K | -100.74K | -11.00K | -48.73K |
| GainOnSaleOfSecurity | 43.02M | 38.64M | 50.92K | 465.78K |
| NetNonOperatingInterestIncomeExpense | -193.39K | -2.25M | -1.56M | -1.49M |
| InterestExpenseNonOperating | 283.13K | 3.16M | 2.53M | 1.49M |
| InterestIncomeNonOperating | 89.74K | 906.15K | 971.48K | |
| OperatingIncome | -67.06M | -71.70M | -53.13M | -63.07M |
| OperatingExpense | 67.12M | 71.70M | 53.13M | 63.07M |
| ResearchAndDevelopment | 27.18M | 41.76M | 26.45M | 42.33M |
| SellingGeneralAndAdministration | 39.94M | 29.94M | 26.67M | 20.74M |
| GeneralAndAdministrativeExpense | 39.94M | 29.94M | 26.67M | 20.74M |
| OtherGandA | 23.28M | 19.05M | 17.75M | 11.62M |
| SalariesAndWages | 16.66M | 10.89M | 8.93M | 9.12M |
| GrossProfit | 57.20K | 0.00 | ||
| CostOfRevenue | 1.36M | 0.00 | ||
| TotalRevenue | 1.41M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 1.41M | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 53.89M | 23.91M | 13.01M | 11.37M |
| ShareIssued | 53.89M | 23.91M | 13.01M | 11.37M |
| NetDebt | 21.86M | 14.51M | 12.16M | |
| TotalDebt | 30.19M | 29.74M | 35.56M | 10.96M |
| TangibleBookValue | -32.19M | -73.08M | -14.44M | 8.74M |
| InvestedCapital | -2.24M | -43.64M | 21.11M | 19.65M |
| WorkingCapital | -28.43M | -15.14M | -15.75M | 7.79M |
| NetTangibleAssets | -32.19M | -73.08M | -14.44M | 8.74M |
| CapitalLeaseObligations | 247.70K | 297.83K | 4.27K | 43.01K |
| CommonStockEquity | -32.19M | -73.08M | -14.44M | 8.74M |
| TotalCapitalization | -32.19M | -73.08M | -14.44M | 8.74M |
| TotalEquityGrossMinorityInterest | -32.19M | -73.08M | -14.44M | 8.74M |
| StockholdersEquity | -32.19M | -73.08M | -14.44M | 8.74M |
| RetainedEarnings | -605.71M | -543.28M | -467.92M | -408.94M |
| AdditionalPaidInCapital | 572.98M | 469.97M | 453.35M | 415.40M |
| CapitalStock | 538.87K | 239.06K | 130.13K | 2.27M |
| CommonStock | 538.87K | 239.06K | 130.13K | 2.27M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 50.77M | 101.90M | 46.74M | 19.79M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.96M | 59.35M | 6.22K | 61.41K |
| DerivativeProductLiabilities | 4.77M | 59.10M | 6.22K | 57.14K |
| LongTermDebtAndCapitalLeaseObligation | 188.80K | 246.92K | 0.00 | 4.27K |
| LongTermCapitalLeaseObligation | 188.80K | 246.92K | 0.00 | 4.27K |
| LongTermDebt | 10.89M | |||
| CurrentLiabilities | 45.81M | 42.55M | 46.73M | 19.73M |
| CurrentDebtAndCapitalLeaseObligation | 30.01M | 29.49M | 35.56M | 10.95M |
| CurrentCapitalLeaseObligation | 58.90K | 50.91K | 4.27K | 38.75K |
| CurrentDebt | 29.95M | 29.44M | 35.55M | 10.92M |
| OtherCurrentBorrowings | 29.95M | 29.44M | 35.55M | 10.92M |
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.03M | 1.01M | 919.97K | 1.98M |
| PayablesAndAccruedExpenses | 12.78M | 12.05M | 10.26M | 6.80M |
| CurrentAccruedExpenses | 2.29M | 2.22M | 1.83M | 1.45M |
| InterestPayable | 0.00 | 12.91K | ||
| Payables | 10.49M | 9.83M | 8.43M | 5.35M |
| TotalTaxPayable | 302.00K | 1.86M | 1.86M | 1.86M |
| IncomeTaxPayable | 302.00K | 1.86M | 1.86M | 1.86M |
| AccountsPayable | 10.19M | 7.97M | 6.57M | 3.49M |
| TotalAssets | 18.58M | 28.82M | 32.30M | 28.53M |
| TotalNonCurrentAssets | 1.20M | 1.41M | 1.32M | 1.01M |
| OtherNonCurrentAssets | 417.52K | 439.28K | 501.30K | 132.01K |
| InvestmentsAndAdvances | 552.18K | 693.19K | 793.93K | 804.93K |
| LongTermEquityInvestment | 552.18K | 693.19K | 793.93K | 804.93K |
| InvestmentsinJointVenturesatCost | 552.18K | 693.19K | 793.93K | 804.93K |
| InvestmentsInOtherVenturesUnderEquityMethod | 853.66K | |||
| NetPPE | 225.51K | 274.64K | 26.17K | 70.36K |
| AccumulatedDepreciation | -1.07M | -903.73K | ||
| GrossPPE | 225.51K | 274.64K | 26.17K | 70.36K |
| OtherProperties | 225.51K | 274.64K | 26.17K | 70.36K |
| CurrentAssets | 17.39M | 27.42M | 30.98M | 27.52M |
| OtherCurrentAssets | 4.48M | 12.49M | 7.59M | 10.12M |
| PrepaidAssets | 10.12M | 7.03M | ||
| Inventory | 3.34M | 0.00 | ||
| FinishedGoods | 29.63K | |||
| WorkInProcess | 958.54K | |||
| RawMaterials | 2.35M | |||
| Receivables | 1.49M | 0.00 | ||
| AccountsReceivable | 1.49M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 8.08M | 14.93M | 23.39M | 17.40M |
| CashAndCashEquivalents | 8.08M | 14.93M | 23.39M | 17.40M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -51.83M | -68.79M | -42.97M | -56.67M |
| RepaymentOfDebt | -36.14M | -4.27K | -10.23M | -12.32M |
| IssuanceOfDebt | 33.10M | 0.00 | 30.00M | 10.00M |
| IssuanceOfCapitalStock | 25.40M | 60.33M | 30.02M | 62.31M |
| InterestPaidSupplementalData | 0.00 | 475.00K | 1.16M | 1.56M |
| EndCashPosition | 8.08M | 14.93M | 23.39M | 17.40M |
| BeginningCashPosition | 14.93M | 23.39M | 17.40M | 14.48M |
| ChangesInCash | -6.84M | -8.46M | 6.00M | 2.92M |
| FinancingCashFlow | 44.98M | 60.33M | 48.97M | 59.59M |
| CashFlowFromContinuingFinancingActivities | 44.98M | 60.33M | 48.97M | 59.59M |
| NetOtherFinancingCharges | -823.89K | -600.00K | -8.03K | |
| ProceedsFromStockOptionExercised | 22.63M | 0.00 | 0.00 | 205.85K |
| NetCommonStockIssuance | 25.40M | 60.33M | 30.02M | 62.31M |
| CommonStockIssuance | 25.40M | 60.33M | 30.02M | 62.31M |
| NetIssuancePaymentsOfDebt | -3.04M | -4.27K | 19.77M | -2.32M |
| NetLongTermDebtIssuance | -3.04M | -4.27K | 19.77M | -2.32M |
| LongTermDebtPayments | -36.14M | -4.27K | -10.23M | -12.32M |
| LongTermDebtIssuance | 33.10M | 0.00 | 30.00M | 10.00M |
| InvestingCashFlow | 0.00 | |||
| CashFlowFromContinuingInvestingActivities | 0.00 | |||
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| OperatingCashFlow | -51.83M | -68.79M | -42.97M | -56.67M |
| CashFlowFromContinuingOperatingActivities | -51.83M | -68.79M | -42.97M | -56.67M |
| ChangeInWorkingCapital | 4.86M | -3.02M | 4.75M | -1.68M |
| ChangeInOtherCurrentLiabilities | -50.13K | 3.41K | -27.00K | -42.85K |
| ChangeInOtherCurrentAssets | -95.25K | -5.90K | -208.20K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 1.82M | 1.89M | 2.37M | 1.45M |
| ChangeInAccruedExpense | 1.71M | 491.73K | -711.66K | 156.14K |
| ChangeInPayable | 111.42K | 1.39M | 3.08M | 1.30M |
| ChangeInAccountPayable | 1.67M | 1.39M | 3.08M | 1.30M |
| ChangeInTaxPayable | -1.55M | 0.00 | 0.00 | |
| ChangeInIncomeTaxPayable | -1.55M | 0.00 | 0.00 | |
| ChangeInPrepaidAssets | 8.01M | -4.90M | 2.62M | -3.09M |
| ChangeInInventory | -3.34M | 0.00 | ||
| ChangeInReceivables | -1.49M | 0.00 | ||
| ChangesInAccountReceivables | -1.49M | 0.00 | ||
| OtherNonCashItems | 33.52M | 2.68M | 1.37M | 1.66M |
| StockBasedCompensation | 8.90M | 5.39M | 5.55M | 7.71M |
| UnrealizedGainLossOnInvestmentSecurities | 6.07M | 2.46M | 3.76M | 882.90K |
| AssetImpairmentCharge | 0.00 | |||
| DepreciationAmortizationDepletion | 117.05K | 113.86K | 44.19K | 204.69K |
| DepreciationAndAmortization | 117.05K | 113.86K | 44.19K | 204.69K |
| OperatingGainsLosses | -42.87M | -1.05M | 537.74K | 608.35K |
| EarningsLossesFromEquityInvestments | 141.01K | 100.74K | 11.00K | 48.73K |
| GainLossOnInvestmentSecurities | -43.02M | -1.15M | -50.92K | -465.78K |
| NetIncomeFromContinuingOperations | -62.42M | -75.37M | -58.98M | -66.05M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OTLK
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|